Kalsiom

Focus: Kalsiom is a French biotechnology company headquartered in Brest specializing in first-in-class monoclonal antibodies. Limited public information available on market position and scale.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Kalsiom

AI assessmentNot Hiring

No open roles listed right now. Follow Kalsiom to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet.

Help build intelligence for Kalsiom

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline on first-in-class monoclonal antibodies offers opportunity to work on novel mechanisms with differentiated therapeutic potential
Location in Brest, France provides access to European biotech ecosystem and potentially lower cost-of-living than major pharma hubs
Early-stage company structure may offer hands-on involvement and faster career progression relative to large organizations

Watch Out For

No active job openings currently available, indicating limited near-term hiring or potential organizational contraction
Lack of disclosed pipeline data, clinical trial data, and financial information raises transparency concerns for assessing company viability and career stability
Pre-revenue biotech status with unknown funding and capitalization creates significant execution and runway risk

Generated by Claude from Kalsiom's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo